Trinity Biotech plc (TRIB)
| Market Cap | 13.32M -11.3% |
| Revenue (ttm) | 48.57M -17.9% |
| Net Income | -36.86M |
| EPS | -1.49 |
| Shares Out | 18.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,484 |
| Open | 0.7350 |
| Previous Close | 0.7433 |
| Day's Range | 0.7100 - 0.7424 |
| 52-Week Range | 0.4800 - 3.4400 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 23, 2026 |
About TRIB
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, v... [Read more]
Financial Performance
In 2024, Trinity Biotech's revenue was $61.56 million, an increase of 8.31% compared to the previous year's $56.83 million. Losses were -$31.79 million, 32.4% more than in 2023.
Financial StatementsNews
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement
DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation
DUBLIN, Ireland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, includin...
Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026
– Reinforces Trinity Biotech's growing position as a key player in diabetes care innovation – Senior commercial executives of Trinity Biotech are attending the World Health Expo from February 10-12, 2...
Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives
- Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition ...
Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests
- TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA 1 positive operations in Q3 2025 and expects to achieve strong ad...
Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances
Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration
Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation
Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, EBITDA Accretion and Cashflow Generation Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion,...
Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test
DUBLIN, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech Welcomes Perceptive Advisor's Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth
DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, in...
Trinity Biotech Appoints Paul Tivnan as Non-Executive Director
DUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
Approval Facilitates Immediate Offshored and Outsourced Manufacturing Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability T...
Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service
New York State Department of Health (NYSDOH) clinical laboratory permit facilitates Q3 2025 launch of the FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test for hypertensive disorders of pregnan...
Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor
Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company's next-generation CGM+ biosensor platform Clinical data confirms...
Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service
FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient...
Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market
WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management soluti...
Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround
-Trinity Biotech projects it reached Adjusted EBITDA 1 -positive operations during Q2 2025 and expects to be Adjusted EBITDA 1 positive going forward, reflecting continued strong execution on its comp...
Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation
Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability
Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable ...
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement
DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearab...
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solution...
Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology
DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, includin...
Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in...
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in...